RUDN Journal of Medicine (Mar 2012)
Clinical trial of fibrinselective thrombolytic pharmaceutical agent «FORTELYZIN®» (III Phase)
Abstract
The clinical trial of fibrinselective thrombolytic agent Fortelyzin® (III phase) showed the comparative efficacy and safety with Actilyse® in patients with acute myocardial infarction and obtained data permitted to recommend it for clinical usage.